Compound ID | 362
Synonym(s): DQ2556 | DQ 2556
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against Enterobacteriaceae; shows no activity against methicillin-resistant Staphylococcus aureus |
| Description: | Cephalosporin-type; comparable or superior to ceftazidime, cefotaxime and cefepime inhibition; Chin NX, Huang HB and Neu HC. In vitro activity and β-lactamase stability of DQ-2556 compared to other agents. 32nd-Intersci-Conf-Antimicrobial-Agents-Chemother 1992; 176 |
| Institute where first reported: | Daiichi Sankyo Pharmaceutical, Japan |
| Year first mentioned: | 1988 |
| Highest development stage: | Phase 2 |
| Development status: | Inactive |
| Reason dropped: | Some frequent side effects: diarrhoea, fever and skin eruptions, was in phase II for parenteral administration in Japan for UTI and then discontinued, this may be due to side effects |